Press "Enter" to skip to content

Statement from FDA Commissioner Scott Gottlieb, M.D. and Director of FDA’s Center for Drug Evaluation and Research Janet Woodcock, M.D., on efforts to modernize generic drug labels while maintaining the efficiency of generic development

FDA announces withdrawal of the proposed rule, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products

Original source: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm628339.htm

Also Read:   FDA Takes Action with Indian Government to Protect Consumers From Illicit Medical Products